21.83
Schlusskurs vom Vortag:
$21.46
Offen:
$21.53
24-Stunden-Volumen:
468.45K
Relative Volume:
0.47
Marktkapitalisierung:
$1.36B
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-377.74M
KGV:
-2.5852
EPS:
-8.4436
Netto-Cashflow:
$-172.35M
1W Leistung:
+19.67%
1M Leistung:
-13.73%
6M Leistung:
-5.30%
1J Leistung:
+182.87%
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ZBIO
Zenas Biopharma Inc
|
21.81 | 1.34B | 10.00M | -377.74M | -172.35M | -8.4436 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.59 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.84 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.59 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
164.04 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Experienced Healthcare Investor Buys Shares Of Zenas Biopharma – Insider Weekends (NASDAQ:ZBIO) - Seeking Alpha
Zenas BioPharma (ZBIO) Price Target Increased by 21.59% to 40.22 - MSN
Zenas BioPharma's Key Milestones and Market Context: Holding Through the BLA (NASDAQ:ZBIO) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Zenas BioPharma Director Makes Bold New Move With Fresh Stock Purchase - TipRanks
Zenas BioPharma Director Increases Stake with $70K Stock Purchase - National Today
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $70,197 By Investing.com - Investing.com Canada
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $70,197 - investing.com
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Director Buys 3,768 Shares of Stock - MarketBeat
Leon Moulder boosts Zenas BioPharma (ZBIO) stake to 4.794% ownership - Stock Titan
Zenas BioPharma (ZBIO) director-affiliated funds purchase 3,768 shares - Stock Titan
Zenas BioPharma (NASDAQ:ZBIO) Trading Up 7.6% Following Insider Buying Activity - MarketBeat
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect | NDAQ:ZBIO | Press Release - Stockhouse
Zenas BioPharma (NASDAQ:ZBIO) Director Purchases $3,000,000.00 in Stock - MarketBeat
Akin, an Elite Global Law Firm - Akin
Zenas BioPharma (ZBIO): Does This $300 Million Raise Clarify or Complicate Its Funding Strategy? - Sahm
Major Insider Move Signals Growing Confidence in Zenas BioPharma’s Future - tipranks.com
Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN
Fairmount fund adds 150,000 Zenas BioPharma (ZBIO) shares - Stock Titan
ZBIO6353884 Bond Price and Chart — FINRA:ZBIO6353884 - TradingView
Zenas BioPharma, Inc. Bonds — Corporate Bond Rates - TradingView
Insider Makes Bold Million-Dollar Bet on Zenas BioPharma - TipRanks
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ZBIO Stock Price and Chart — NASDAQ:ZBIO - TradingView
54K-share open-market buy by CEO-linked entities at Zenas BioPharma (ZBIO) - Stock Titan
Zenas BioPharma Raises Capital via Notes and Equity Offering - tipranks.com
Zenas BioPharma (ZBIO) CEO Moulder buys shares worth $1.02 million By Investing.com - Investing.com Australia
Zenas BioPharma (ZBIO) CEO Moulder buys shares worth $1.02 million - investing.com
Lu Hongbo buys $1.5 million in Zenas Biopharma (ZBIO) stock - investing.com
Lu Hongbo buys $1.5 million in Zenas Biopharma (ZBIO) stock By Investing.com - Investing.com Canada
Director-linked funds add 75K Zenas BioPharma (ZBIO) shares at $20 in offering - Stock Titan
Zenas BioPharma (ZBIO) raises capital via $200M converts and equity sale - Stock Titan
Form 424B5 Zenas BioPharma, Inc. - StreetInsider
Zenas BioPharma (NASDAQ: ZBIO) prices $200M convertible notes due 2032 - Stock Titan
[424B5] Zenas BioPharma, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma announces concurrent public offerings of convertible senior notes and common stock - MSN
Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk - Yahoo Finance
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Zenas BioPharma prices $300M capital raise in dual offering - MSN
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap DownShould You Sell? - MarketBeat
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Zenas BioPharma prices $200M convertible notes, $100M stock sale By Investing.com - Investing.com Canada
Zenas BioPharma Stock Pre-Market (-9.5%): Announces Concurrent Stock and Debt Offerings - Trefis
Zenas BioPharma Prices $287.5 Million Convertible Notes, Equity Offerings - MarketScreener
Zenas BioPharma prices $200M convertible notes, $100M stock sale - Investing.com
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million - The Manila Times
Zenas BioPharma launches convertible notes, stock offerings By Investing.com - ca.investing.com
Zenas BioPharma Announces Pricing of Concurrent Public - GlobeNewswire
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Buy |
20.00 |
150,000 |
3,000,000 |
2,359,025 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 31 '26 |
Buy |
19.31 |
34,000 |
656,540 |
1,726,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 30 '26 |
Buy |
18.23 |
20,000 |
364,600 |
1,692,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
20.00 |
75,000 |
1,500,000 |
422,968 |
| Lu Hongbo | Director |
Feb 11 '26 |
Buy |
22.50 |
25,985 |
584,662 |
347,968 |
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 02 '26 |
Buy |
17.96 |
57,000 |
1,023,720 |
423,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 07 '26 |
Buy |
16.38 |
50,000 |
819,000 |
316,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 08 '26 |
Buy |
16.30 |
30,000 |
489,000 |
346,155 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):